Effects of Cox-2 Inhibitors on Bladder Cancer
Author Information
Author(s): Adhim Z, Matsuoka T, Bito T, Shigemura K, Lee K-M, Kawabata M, Fujisawa M, Nibu K, Shirakawa T
Primary Institution: Kobe University Graduate School of Medicine
Hypothesis
The study investigates the effect of Cox-2 inhibitors on reversing epithelial-to-mesenchymal transition (EMT) and inhibiting tumor growth in bladder cancer cells.
Conclusion
Etodolac at clinical doses exhibited induced in vitro and in vivo anti-tumor effects and reversal effect of EMT in T24 cells.
Supporting Evidence
- Etodolac showed the highest tumor growth inhibition in T24 cells in vivo.
- Etodolac reduced SNAIL mRNA and vimentin expression while inducing E-cadherin expression.
- Cell migration was significantly inhibited by etodolac treatment.
Takeaway
This study found that a drug called etodolac can help stop bladder cancer cells from growing and changing into a more dangerous form.
Methodology
The study used three Cox-2 inhibitors on three human bladder cancer cell lines and a mouse model to assess their effects on tumor growth and EMT.
Limitations
The study primarily focused on one cell line (T24) and may not fully represent the effects on other bladder cancer types.
Participant Demographics
The study involved athymic BALB/c mice and human bladder cancer cell lines.
Statistical Information
P-Value
P<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website